Skip to main content
Top
Published in: Diabetologia 6/2014

01-06-2014 | Short Communication

The effectiveness of structured personal care of type 2 diabetes on recurrent outcomes: a 19 year follow-up of the study Diabetes Care in General Practice (DCGP)

Authors: Hanna Lundström, Volkert Siersma, Anni B. Sternhagen Nielsen, John Brodersen, Susanne Reventlow, Per K. Andersen, Niels de Fine Olivarius

Published in: Diabetologia | Issue 6/2014

Login to get access

Abstract

Aims/hypothesis

The estimation of effect size in clinical trials commonly disregards recurrent outcomes. We investigated the effectiveness of a complex intervention on recurrent outcomes in patients with type 2 diabetes.

Methods

In the Diabetes Care in General Practice (DCGP) randomised controlled trial, 1,381 patients newly diagnosed with type 2 diabetes were randomised to 6 years of structured personal care or routine care (ClinicalTrials.gov NCT01074762). The trial had 19 years of registry-based follow-up and was analysed with Cox regression models. Repeated occurrences in the same patient of outcomes (any diabetes-related endpoint, myocardial infarction [MI], stroke, peripheral vascular disease and microvascular disease) were accounted for with the Wei, Lin and Weissfeld method.

Results

As previously shown, the intervention reduced the rates of first occurrence of both MI and any diabetes-related endpoint. However, for all outcomes, the HR for a second event showed a statistically non-significant tendency to be increased. We estimated a combined HR for all marginal failure times, regardless of whether they were first, second or later events. This showed that the intervention had no effect on the rate of any of the outcomes, including MI (HR 0.89, 95% CI 0.76, 1.05) and any diabetes-related endpoint (HR 0.98, 95% CI 0.87, 1.09).

Conclusions/interpretation

In the DCGP study, a smaller proportion of patients who received structured care experienced a first occurrence of MI or any diabetes-related endpoint compared with patients who received routine care. However, the patients who received structured care tended to experience more recurrent outcomes, so the total outcome rate was not affected by the intervention.
Appendix
Available only for authorised users
Literature
1.
go back to reference van der Heijden AA, Van’t Riet E, Bot SD et al (2013) Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study. Diabetes Care 36:3498–3502PubMedCrossRef van der Heijden AA, Van’t Riet E, Bot SD et al (2013) Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study. Diabetes Care 36:3498–3502PubMedCrossRef
2.
go back to reference Simmons RK, Sharp SJ, Sandbaek A et al (2012) Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial. Diabet Med 29:e409–e416PubMedCentralPubMedCrossRef Simmons RK, Sharp SJ, Sandbaek A et al (2012) Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial. Diabet Med 29:e409–e416PubMedCentralPubMedCrossRef
3.
go back to reference Wei LJ, Lin DY, Weissfeld L (1989) Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 84:1065–1073CrossRef Wei LJ, Lin DY, Weissfeld L (1989) Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 84:1065–1073CrossRef
4.
go back to reference Hansen LJ, Siersma V, Beck-Nielsen H, de Fine Olivarius N (2013) Structured personal care of type 2 diabetes: a 19 year follow-up of the study Diabetes Care in General Practice (DCGP). Diabetologia 56:1243–1253PubMedCrossRef Hansen LJ, Siersma V, Beck-Nielsen H, de Fine Olivarius N (2013) Structured personal care of type 2 diabetes: a 19 year follow-up of the study Diabetes Care in General Practice (DCGP). Diabetologia 56:1243–1253PubMedCrossRef
5.
go back to reference Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378:156–167PubMedCentralPubMedCrossRef Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378:156–167PubMedCentralPubMedCrossRef
6.
go back to reference Kohli P, Wallentin L, Reyes E et al (2013) Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation 127:673–680PubMedCrossRef Kohli P, Wallentin L, Reyes E et al (2013) Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation 127:673–680PubMedCrossRef
7.
go back to reference LaRosa JC, Deedwania PC, Shepherd J et al (2010) Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 105:283–287PubMedCrossRef LaRosa JC, Deedwania PC, Shepherd J et al (2010) Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 105:283–287PubMedCrossRef
8.
go back to reference Murphy SA, Antman EM, Wiviott SD et al (2008) Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 29:2473–2479PubMedCentralPubMedCrossRef Murphy SA, Antman EM, Wiviott SD et al (2008) Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 29:2473–2479PubMedCentralPubMedCrossRef
9.
go back to reference Pandeya N, Purdie DM, Green A, Williams G (2005) Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial. Am J Epidemiol 161:748–754PubMedCrossRef Pandeya N, Purdie DM, Green A, Williams G (2005) Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial. Am J Epidemiol 161:748–754PubMedCrossRef
10.
go back to reference Mendis S, Thygesen K, Kuulasmaa K et al (2011) World Health Organization definition of myocardial infarction: 2008–09 revision. Int J Epidemiol 40:139–146PubMedCrossRef Mendis S, Thygesen K, Kuulasmaa K et al (2011) World Health Organization definition of myocardial infarction: 2008–09 revision. Int J Epidemiol 40:139–146PubMedCrossRef
11.
go back to reference Wei LJ, Glidden DV (1997) An overview of statistical methods for multiple failure time data in clinical trials. Stat Med 16:833–839PubMedCrossRef Wei LJ, Glidden DV (1997) An overview of statistical methods for multiple failure time data in clinical trials. Stat Med 16:833–839PubMedCrossRef
Metadata
Title
The effectiveness of structured personal care of type 2 diabetes on recurrent outcomes: a 19 year follow-up of the study Diabetes Care in General Practice (DCGP)
Authors
Hanna Lundström
Volkert Siersma
Anni B. Sternhagen Nielsen
John Brodersen
Susanne Reventlow
Per K. Andersen
Niels de Fine Olivarius
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 6/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3204-1

Other articles of this Issue 6/2014

Diabetologia 6/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.